Results: Acute myeloid leukemia (AML) was the most common indication for haplo (76%) and approximately 45% of patients were transplanted in CR1.
PT-CY was given on Day+3 and Day+5 in group-1 and on day+3 and day+4 in group-2 and 3. Transplants were performed from 2006-2017 and median follow up is 21 months (range 11-36). Patients were divided into 3 groups: received cyclosporine A-mycofenolate-mofetil(CSA+MMF) initiated at day+1 (group-1, n=124) or CSA+MMF both started at day+5 (group-2, n=170) and tacrolimus + MMF from day+5 (group-3, n=215). Methods: Study aim was to evaluate the schedule of IST given in combination with PT-Cy as GVHD-prophylaxis post-haplo for acute leukemia (AL) and reported to the ALWP/EBMT registry. However, the combined immunosuppressive compounds (IST) used as GVHD-prophylaxis and the post-transplant initiation day varies and is not fully standardized.
1 Ospedale Pediatrico Bambin Gesú, Roma, Italy, 2 Saint Antoine Hospital, Paris, France, 3 BMT Unit, Muenchen, Germany, 4 BMT Unit, Madrid, Spain, 5 Le Molinette, Torino, Italy, 6 Universita Cattolica, Roma, Italy, 7 Humanitas Clinical and Research Center Rozzano, Milano, Italy, 8 BMT Unit, St Petersburg, Russian Federation, 9 BMT Unit, Prague, Czech Republic, 10 BMT Unit, Barcelona, Spain, 11 Sheba Medical Center, Tel Aviv, Israelīackground: Post-transplant-Cyclophosphamide (PT-Cy) is being used successfully in the setting of unmanipulated haploidentical-transplant (haplo) as graft-versus-host-disease(GVHD) prophylaxis.
0 kommentar(er)
